Cramer Dissects Disney
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$1.70 -0.05 | -2.86%
02/09/12 - 03:59 PM ET
621.97K / 1.06M
Vol / Avg. Vol:1.75 / 1.75
Open / Prev. Close:1.70 - 1.77
Today's Range:1.35 - 2.68
52 Wk Range:13.64%
Performance YTD:TheStreet Rating:
Portfolios with AEZS
- Portfolio NameUser Type
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
- UserMy Portfolio
- Contributor4 Biotech Penny Stocks to Buy
- Contributor10 Cheap Stocks to Buy for ...
- UserBunny Money
- Usergdean1
Latest AEZS Headlines from TheStreet
- 10 Biotech Stock Predictions for 2012 12.20.11 | 11:12 am
- Biotech Stock Mailbag: Prostate Cancer Drug Reaction 11.04.11 | 05:11 am
- Keryx: Readers React to Perifosine Prediction 10.19.11 | 07:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Keryx Pharma Loses Its Top Shareholder 10.11.11 | 01:10 pm
- Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks 09.30.11 | 05:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 08.08.11 | 10:08 am
- 10 Pharma Stocks Under $3 06.16.11 | 01:06 pm
- 10 Cheap Stocks to Buy for Under $1.99 04.20.11 | 03:04 pm
Press Releases for AEZS
- Aeterna Zentaris To Present At BIO CEO Investor And RBC Capital Markets Global Healthcare Conferences In New York - PR Newswire 02.07.12 | 07:02 am
- Aeterna Zentaris Reports Updated Phase 1 Trial Results For AEZS-108 In Castration- And Taxane-Resistant Prostate Cancer At ASCO GCS Meeting - PR Newswire 02.03.12 | 07:02 am
- Aeterna Zentaris Announces Collaboration With Ventana Medical Systems, Inc. To Develop Companion Diagnostic In Cancer For AEZS-108 - PR Newswire 01.05.12 | 07:01 am
- Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial With Perifosine In Colorectal Cancer In Japan - PR Newswire 01.03.12 | 07:01 am
- Aeterna Zentaris: Encouraging Clinical Data For Perifosine In Hodgkin Lymphoma Presented At ASH Meeting - PR Newswire 12.13.11 | 08:12 am
- Aeterna Zentaris: Encouraging Preclinical Data For Perifosine In Hodgkin Lymphoma Presented At ASH Meeting - PR Newswire 12.12.11 | 08:12 am
- Aeterna Zentaris: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase 2A Trial With AEZS-130 In Cancer Cachexia - PR Newswire 11.28.11 | 07:11 am
- Aeterna Zentaris And Hikma Pharmaceuticals Sign A Commercialization And Licensing Agreement For Lead Oncology Compound, Perifosine, For Middle East And North Africa (MENA) Region - PR Newswire 11.23.11 | 07:11 am
- Aeterna Zentaris To Present At Upcoming Piper Jaffray And Oppenheimer Healthcare Conferences In New York - PR Newswire 11.22.11 | 07:11 am
- Aeterna Zentaris To Report Third Quarter 2011 Financial And Operating Results On November 10, 2011 - PR Newswire 11.03.11 | 07:11 am
Partner Headlines for AEZS
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 02.01.12 | 09:02 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 01.26.12 | 09:01 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- 7 Stocks Below $10 That Analysts Expect To Double - Seeking Alpha 12.05.11 | 08:12 am
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Keryx Biopharmaceuticals: Volatility Could Potentially Produce Monetary Gains - Seeking Alpha 10.23.11 | 09:10 am
- Due Diligence And Speculative Biotech Investing - Seeking Alpha 09.27.11 | 08:09 am
- Has Taseko Mines Struck Gold? - Seeking Alpha 09.15.11 | 08:09 am
- Gambling With Speculative Healthcare Stocks - Seeking Alpha 09.06.11 | 09:09 am
- Add Questcor To Your Diversified High-Growth Biotech Portfolio - Seeking Alpha 08.28.11 | 06:08 am
